OCS NASDAQ
Credit Risk of going bust: lower than 70% of companies Debt: 0.6% of company value Bonds: none of note held by US funds details ▾
Total debt $3.1M against a stock market value of $490.2M.
Distance to default 7.59 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.5M (short-term plus half of long-term), stock volatility 73.3%; Altman Z'' 5.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Zug, ZG 6300
CH
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
